Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.

塞库金单抗 医学 银屑病 银屑病面积及严重程度指数 安慰剂 注射器 随机对照试验 内科学 皮肤病科 病理 精神科 替代医学 银屑病性关节炎
作者
Alice B. Gottlieb,Andrew Blauvelt,Jörg C. Prinz,P. Papanastasiou,Rashidkhan Pathan,Judit Nyirady,Todd Fox,C. Papavassilis
出处
期刊:PubMed 卷期号:15 (10): 1226-1234 被引量:30
链接
标识
摘要

Secukinumab, a human monoclonal antibody that selectively targets interleukin-17A, is highly efficacious in the treatment of moderate-to-severe psoriasis, starting at early time points, with a sustained effect and a favorable safety profile.Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg, or placebo self-administered by prefilled syringe at baseline, weeks 1, 2, and 3, and then every four weeks from week 4 to 48. Efficacy responses (≥ 75/90/100% improvement in Psoriasis Area and Severity Index [PASI 75/90/100] and clear/almost clear skin by Investigator's Global Assessment 2011 modified version [IGA mod 2011 0/1]) were measured to week 52. Patient-reported usability of the prefilled syringe was evaluated by the Self-Injection Assessment Questionnaire to week 48.The efficacy of secukinumab increased to week 16 and was maintained to week 52. With secukinumab 300 mg at week 52, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 83.5%/68.0%/47.5% and 71.5% of patients when analyzed by multiple imputation, respectively, and by 75.9%/62.1%/43.1% and 63.8% of patients when analyzed by nonresponder imputation, respectively. With secukinumab 150 mg at week 52, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 63.5%/50.3%/31.1% and 43.6% of patients when analyzed by multiple imputation, respectively, and by 61.0%/49.2%/30.5% and 42.4% of patients when analyzed by nonresponder imputation, respectively. Self-reported acceptability of the prefilled syringe was high throughout the study. The incidence of adverse events (AE) was well balanced between groups, with AEs reported in 74.4% of patients receiving secukinumab 300 mg and 77.3% of patients receiving secukinumab 150 mg. Nasopharyngitis was the most common AE across both secukinumab groups.Self-administration of secukinumab by prefilled syringe was associated with robust and sustained efficacy and a favorable safety profile up to week 52.

J Drugs Dermatol. 2016;15(10):1226-1234.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JasonSun完成签到,获得积分10
1秒前
2秒前
2秒前
2秒前
Only发布了新的文献求助10
3秒前
3秒前
WLX发布了新的文献求助10
4秒前
tonyhuang完成签到,获得积分10
4秒前
胡小壳应助科研通管家采纳,获得10
5秒前
Hello应助科研通管家采纳,获得10
5秒前
搜集达人应助科研通管家采纳,获得30
5秒前
华仔应助科研通管家采纳,获得10
5秒前
脑洞疼应助科研通管家采纳,获得10
5秒前
orixero应助科研通管家采纳,获得10
5秒前
Lucas应助科研通管家采纳,获得10
5秒前
缥缈青文完成签到,获得积分10
5秒前
汉堡包应助科研通管家采纳,获得10
5秒前
传奇3应助科研通管家采纳,获得10
5秒前
田様应助科研通管家采纳,获得10
5秒前
5秒前
Akim应助科研通管家采纳,获得10
5秒前
香蕉觅云应助科研通管家采纳,获得10
5秒前
CodeCraft应助科研通管家采纳,获得10
6秒前
在水一方应助科研通管家采纳,获得10
6秒前
桐桐应助Dr.Liujun采纳,获得10
6秒前
6秒前
orixero应助Leslie采纳,获得10
7秒前
英姑应助林婉仪采纳,获得10
7秒前
kerio发布了新的文献求助10
7秒前
8秒前
简单小土豆完成签到,获得积分10
8秒前
爆米花应助FelixZhou采纳,获得10
8秒前
粗犷的沛容应助scy采纳,获得20
9秒前
9秒前
无辜善愁发布了新的文献求助10
10秒前
啦啦啦发布了新的文献求助10
12秒前
科研通AI2S应助独特斩采纳,获得10
12秒前
ozz完成签到,获得积分10
13秒前
zhaoyang完成签到,获得积分10
16秒前
蝌蚪完成签到,获得积分10
16秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
A Dissection Guide & Atlas to the Rabbit 600
中国心血管健康与疾病报告2023(要完整的报告) 500
Development of a new synthetic process for the synthesis of (S)-methadone and (S)- and (R)-isomethadone as NMDA receptor antagonists for the treatment of depression 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3102795
求助须知:如何正确求助?哪些是违规求助? 2754032
关于积分的说明 7626280
捐赠科研通 2406879
什么是DOI,文献DOI怎么找? 1277068
科研通“疑难数据库(出版商)”最低求助积分说明 617041
版权声明 599103